Skip to main content

Table 4 Recurrences in patients treated with chemoradiotherapy

From: Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa

PS Location ER RT field Dose Recurrence site DFS Treatment for recurrence
0 Mt ENI 60.0 Local 0 Surgery
1 Mt + ENI 28.0 Lung 6.1 Surgery
0 Ut Non-ENI 40.0 Local 7.2 ESD
0 Mt + ENI 40.0 #104R 13.1 Chemotherapy
0 Lt + ENI 39.6 #3, #7 15.3 Surgery
0 Ut + ENI 50.4 #101R 19.8 Chemotherapy
0 Mt + ENI 40.0 #109R 22.5 Chemotherapy
0 Mt + ENI 39.6 #104R 28.5 Chemotherapy
0 Mt + ENI 65.0 #104R 30.7 Chemotherapy
0 Mt + Non-ENI 40.0 #104R 31.0 Chemotherapy
0 Mt + ENI 39.6 Local 43.2 ESD
1 Lt Non-ENI 65.0 #106recR 58.3 Chemotherapy
0 Mt + ENI 40.0 Local 75.1 ESD
  1. Lymph node metastasis was recorded according to the Japanese Society for Esophageal Diseases classification of esophageal cancer, 10th edition. #104: supraclavicular LNs (lymph nodes), #3: LNs along the lesser curvature, #7: LNs along the left gastric artery, #101: cervical paraesophageal LNs, #109: main bronchus LNs, #106rec: recurrent nerve LNs. DFS disease-free survival (months), Dose radiotherapy dose (Gy), ER endoscopic resection, ESD endoscopic submucosal dissection, Lt lower thoracic esophagus, Mt middle thoracic esophagus, PS Performance status, RT field radiotherapy field, Ut upper thoracic esophagus